Clinical trial
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of…
NCT00035256 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00035256 |
|---|---|
| Title | Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis |
| Official title | Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | teriparatide, raloxifene HCl, placebo |
| Enrollment | 330 |
| Start date | Oct 1, 2001 |
| Completion | Jul 1, 2005 |
| First posted | May 3, 2002 |
| Last update posted | May 15, 2007 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: